Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H- pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists

Journal of Medicinal Chemistry

Volumn 51, Issue 17, 2008, Pages 5397-5412

  Tseng, Shi Liang ^a   Hung, Ming Shiu ^a   Chang, Chun Ping ^a   Song, Jen Shin ^a   Tai, Chia Liang ^a   Chiu, Hua Hao ^a   Hsieh, Wan Ping ^a   Lin, Yinchiu ^a   Chung, Wan Ling ^a   Kuo, Chun Wei ^a   Wu, Chien Huang ^a   Chu, Cheng Ming ^a   Tung, Yen Shih ^a   Chao, Yu Sheng ^a   Shia, Kak Shan ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 4 ETHYL 5 [5 (PENT 1 YNYL)THIOPHEN 2 YL](PIPERIDIN 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 4 METHYL 5 [5 (4 METHYLPENT 1 YNYL)THIOPEN 2 YL] (PIPERIDIN 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR ANTAGONIST; PYRAZOLE DERIVATIVE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; WEIGHT REDUCTION;

ANIMALS; BINDING SITES; HYDROPHOBICITY; MICE; MICE, OBESE; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES; WEIGHT LOSS;

EID: 51849098198     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800066v     Document Type: Article

References (55)

1. (a) Van Gaal, L. F. Reducing cardiometabolic risk through selective antagonism of CB1 receptors. Clin. Cornerstone 2007, 8 (Suppl. 6), S24-S29.
2. (b) Overweight and Obesity. Centers for Disease Control and Prevention. http://www.cdc.gov/nccdphp/dnpa/obesity/.
3. Antel, J.; Gregory, P. C.; Nordheim, U. CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders. J. Med. Chem. 2006, 49, 4008-4016.
4. Nilsson, B. M. 5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents. J. Med. Chem. 2006, 49, 4023-4034.
5. Nargund, R. P.; Strack, A. M.; Fong, T. M. Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity. J. Med. Chem. 2006, 49, 4035-4043.
6. Handlon, A. L.; Zhou, H. Melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity. J. Med. Chem. 2006, 49, 4017-4022.
7. (a) Lan, R.; Liu, Q.; Fan, P.; Lin, S.; Fernando, S. R.; McCallion, D.; Pertwee, R.; Makriyannis, A. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem. 1999, 42, 769-776.
8. (b) Kotagiri, V. K.; Suthrapu, S.; Reddy, J. M.; Rao, C. P.; Bollugoddu, V.; Bhattacharya, A.; Bandichhor, R. An improved synthesis of rimonabant: anti-obesity drug. Org. Process Res. Dev. 2007, 11, 910-912.
9. Colombo, G.; Agabio, R.; Diaz, G.; Lobina, C.; Reali, R.; Gessa, G. L. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci. 1998, 63, 113-117.
10. Trillou, R. C.; Arnone, M.; Delgorge, C.; Gonalons, N.; Keane, P.; Maffrand, J. P.; Soubrie, P. Anti-obestity effect of SR141716A, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol.: Regul. Integr. Comp. Physiol. 2003, 284, 345-353.
11. 36f The newly developed alkynylthiophenes described in this paper, showing ability to switch functional properties between partial agonists, neutral antagonists, and inverse agonists under minor structural modifications, might help facilitate current studies on important issues about whether the suppression of feeding produced by CB1 neutral antagonists or partial agonists is still accompanied by adverse effects observed with rimonabant.
12. Van Gaal, L. F.; Rissanen, A. M.; Scheen, A. J.; Ziegler, O.; Rossner, S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365, 1389-1397.
13. Pagotto, U.; Pasquali, R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet 2005, 365, 1363-1364.
14. Smith, R. A.; Fathi, Z. Recent advances in the research and development of CB1 antagonists. 1Drugs 2005, 8, 53-66.
15. 36d-f
16. Scheen, A. J.; Finer, N.; Hollander, P.; Jensen, M. D.; Van Gaal, L. F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368, 1660-1672.
17. Oper, A. Where now for new drugs for atherosclerosis? Nat. Rev. Drug Discovery 2007, 6, 334-335.
18. Cohen, C.; Perrault, G.; Voltz, C.; Steinberg, R.; Soubrie, P. SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine releasing effects of nicotine in rats. Behav. Pharmacol. 2002, 13, 451-463.
19. Hungund, B. L.; Basavarajappa, B. S.; Vadasz, C.; Kunos, G.; Rodriguez de Fonseca, F.; Colombo, G.; Serra, S.; Parsons, L.; Koob, G. F. Ethanol, endocannabinoids, and the cannabinoidergic signaling system. Alcohol.: Clin. Exp. Res. 2002, 26, 565-574.
20. Le Foll, B.; Goldberg, S. R. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J. Pharmacol. Exp. Ther. 2005, 312, 875-883.
21. Castellano, C.; Rossi-Arnaud, C.; Cestari, V.; Costanzi, M. Cannabinoids and memory: animal studies. Curr. Drug. Targets: CNS Neurol. Disord. 2003, 2, 389-402.
22. Fatima, T. C.; Boris, J.; Pascal, G.; Jeanne, T. V. N.; Vanessa, D.; Liying, L.; Valerie, S. L.; Catherine, L.; Ariane, M.; Sophie, L. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. 2006, 12, 671-676.
23. Lambert, D. M. CB1 Cannabinoid receptor antagonism for treating inflammation and arthritis. Expert Opin. Ther. Pat. 2007, 17, 1027-1031, and references therein.
24. For recent reviews, see the following: (a) Lange, J. H. M.; Kruse, C. G. Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discovery Today 2005, 10, 693-702.
25. (b) Muccioli, G. G.; Lambert, D. M. Latest advances in cannabinoid receptor antagonists and inverse agonists. Expert Opin. Ther. Pat. 2006, 16, 1405-1423.
26. (c) Högenauer, E. K. Latest advances in the cannabinoids. Expert Opin. Ther. Pat. 2007, 17, 1457-1476.
27. Lange, J. H. M.; vanStuivenberg, H. H.; Coolen, H. K. A. C.; Adolfs, T. J. P.; McCreary, A. C.; Keizer, H. G.; Wals, H. C.; Veerman, W.; Borst, A. J. M.; DeLooff, W.; Verveer, P. C.; Kruse, C. G. Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists. J. Med. Chem. 2005, 48, 1823-1838.
28. Plummer, C. W.; Finke, P. E.; Mills, S. G.; Wang, J.; Tong, X.; Doss, G. A.; Fong, T. M.; Lao, J. Z.; Schaeffer, M. T.; Chen, J.; Shen, C. P.; Stribling, D. S.; Shearman, L. P.; Strack, A. M.; Van der Ploeg, L. H. Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists. Bioorg. Med. Chem. Lett. 2005, 15, 1441-1446.
29. (a) Lazzari, P.; Rulu, S.; Pinna, A. G.; Murineddu, G. Pharmaceutical Compounds. U.S. Patent 20050261281, 2005.
30. (b) Tai, C. L.; Hung, M. S.; Pawar, V. D.; Tseng, S. L.; Song, J. S.; Hsieh, W. P.; Chiu, H. H.; Wu, H. C.; Hsieh, M. T.; Kuo, C. W.; Hsieh, C. C.; Tsao, J. P.; Chao, Y. S.; Shia, K. S. Design, synthesis, and biological evaluation of novel alkenylthiophenes as potent and selective CB1 cannabinoid receptor antagonists. Org. Biomol. Chem. 2008, 6, 447-450.
31. (c) Xia, M.; Liotta, F.; Pan, M.; Wachter, M. P.; Lu, H. Substituted 5-Heteroaryl-1-phenyl-pyrazole Cannabinoid Modulators. WO Patent 2007061948, 2007.
32. (a) Thornber, C. W. Isosterism and molecular modification in drug design. Chem. Soc. Rev. 1979, 8, 563-580.
33. (b) Moreira, L. M.; Barreiro, E. J. Bioisosterism: a useful strategy for molecular modification and drug design. Curr. Med. Chem. 2005, 12, 23-49.
34. (c) Patani, G. A.; LaVoie, E. J. Bioisosterism: a rational approach in drug design. Chem. Rev. 1996, 96, 3147-3176.
35. (d) Hernandez, M. A.; Rathinavelu, A. Basic Pharmacology: Understanding Drug Action and Reaction; Taylor & Francis Group: Boca Raton, FL, 2006; Chapter 3, pp 68-71.
36. (e) Burger, A. Isosterism and bioisosterism in drug design. Prog. Drug Res. 1991, 37, 287-371.
37. 3/KF. Org. Lett. 2005, 7, 5083-5085.
38. Littke, A. F.; Fu, G. C. Palladium-catalyzed coupling reactions of aryl chlorides. Angew. Chem., Int. Ed. 2002, 41, 4176-4211.
39. Shim, J. Y.; Welsh, W. J.; Cartier, E.; Edwards, J. L.; Howlett, A. C. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4- chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl- 1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor. J. Med. Chem. 2002, 45, 1447-1459.
40. Hurst, D. P.; Lynch, D. L.; Barnett-Norris, J.; Hyatt, S. M.; Seltzman, H. H.; Zhong, M.; Song, Z. H.; Nie, J.; Lewis, D.; Reggio, P. H. N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol. Pharmacol. 2002, 62, 1274-1287.
41. 27,28 molecular modeling studies on 5-alkyl, 5-alkenyl, and 5-alkynylthiophene derivatives in the CB1 receptor homology model are currently being carried out in our laboratories. Preliminary results revealed that among various aliphatic substituents on the thiophene ring, the alkynyl group appeared to be the most appropriate choice in the system described above.
42. Hurst, D.; Umejiego, U.; Lynch, D.; Seltzman, H.; Hyatt, S.; Roche, M.; McAllister, S.; Fleischer, D.; Kapur, A.; Abood, M.; Shi, S.; Jones, J.; Lewis, D.; Reggio, P. Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine 3.28(192) interaction. J. Med. Chem. 2006, 49, 5969-5987, and references therein.
43. Preliminary results indicated that unlike rimonabant showing adverse side effects at an oral dose of 30 mg/kg, compound 18 was well tolerated up to 50 mg/kg without inducing hypothermia or severe reduction in locomotor activity in C57BL/6 mice.
44. Felder, C. C.; Joyce, K. E.; Briley, E. M.; Mansouri, J.; Mackie, K.; Blond, O.; Lai, Y.; Ma, A. L.; Mitchell, R. L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 1995, 48, 443-450.
45. Frang, H.; Mukkala, V. M.; Syysto, R.; Ollikka, P.; Hurskainen, P.; Scheinin, M.; Hemmila, I. Nonradioactive GTP binding assay to moniter activation of G protein-coupled receptoers. Assay Drug Dev. Technol. 2003, 1, 275-280.
46. (a) Govaerts, S. J.; Hermans, E.; Lambert, D. M. Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. Eur. J. Pharm. Sci. 2004, 23, 233-243.
47. (b) Landsman, R. S.; Burkey, T. H.; Consroe, P.; Roeske, W. R.; Yamamura, H. I. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 1997, 334, R1-R2.
48. (c) Mato, S.; Pazos, A.; Valdizán, E. M. Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain. Eur. J. Pharmacol. 2002, 443, 43-46.
49. (d) Kenakin, T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FESEB J. 2001, 15, 598-611.
50. (e) de Ligt, R. A.; Uzerman, A. P. Intrinsic activity at adenosine A1 receptors: partial and inverse agonism. Curr. Pharm. Des. 2002, 8, 2333-2344.
51. (f) Salamone, J. D.; McLaughlin, P. J.; Sink, K.; Makriyannis, A.; Parker, L. A. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol. Behav. 2007, 91, 383-388, and references therein.
52. (g) Muccioli, G. G.; Wouters, J.; Charlier, C.; Scriba, G. K. E.; Pizza, T.; Di Pace, P.; De Martino, P.; Poppitz, W.; Poupaert, J. H.; Lambert, D. M. Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists. J. Med. Chem. 2006, 49, 872-882.
53. 38 the vehicle formulas, containing either 10% or 20% of DMSO, are found to be well tolerated in rats and mice.
54. (a) Costa, B.; Trovato, A. E.; Colleoni, M.; Giagnoni, G.; Zarini, E.; Croci, T. Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 2005, 116, 52-61.
55. (b) McLaughlin, P. J.; Winston, K. M.; Limebeer, C. L.; Parker, L. A.; Makriyannis, A.; Salamone, J. D. The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology (Berlin) 2005, 180, 286-293.